

# Ulrich Brinkmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5056583/publications.pdf>

Version: 2024-02-01

148  
papers

11,529  
citations

41344

49  
h-index

28297

105  
g-index

150  
all docs

150  
docs citations

150  
times ranked

9945  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3473-3478.	7.1	1,099
2	Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter Gene <i>ABCB1</i> . New England Journal of Medicine, 2003, 348, 1442-1448.	27.0	690
3	Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clinical Pharmacology and Therapeutics, 2001, 69, 169-174.	4.7	628
4	The making of bispecific antibodies. MAbs, 2017, 9, 182-212.	5.2	626
5	Bispecific antibodies. Drug Discovery Today, 2015, 20, 838-847.	6.4	473
6	A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies. Analytical Biochemistry, 1992, 205, 263-270.	2.4	365
7	High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene, 1989, 85, 109-114.	2.2	363
8	Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology, 2003, 124, 26-33.	1.3	309
9	Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clinical Pharmacology and Therapeutics, 2002, 72, 584-594.	4.7	279
10	Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet, The, 2001, 358, 383-384.	13.7	260
11	Association of the P-Glycoprotein Transporter MDR1 C3435T Polymorphism with the Susceptibility to Renal Epithelial Tumors. Journal of the American Society of Nephrology: JASN, 2002, 13, 1847-1854.	6.1	233
12	<i>MDR1</i> gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. British Journal of Clinical Pharmacology, 2002, 53, 526-534.	2.4	226
13	B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 8616-8620.	7.1	225
14	A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7538-7542.	7.1	225
15	Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics and Genomics, 2001, 11, 111-121.	5.7	204
16	Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics and Genomics, 2002, 12, 591-595.	5.7	194
17	ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics, 2001, 2, 51-64.	1.3	186
18	Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 10427-10431.	7.1	169

#	ARTICLE	IF	CITATIONS
19	Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. <i>MABs</i> , 2012, 4, 653-663.	5.2	168
20	Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. <i>Gene</i> , 1993, 128, 43-49.	2.2	165
21	Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 557-565.	5.7	162
22	Digoxin pharmacokinetics and MDR1 genetic polymorphisms. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 809-812.	1.9	149
23	Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments. <i>Nature Biotechnology</i> , 1996, 14, 1239-1245.	17.5	143
24	Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. <i>Biochemistry</i> , 1994, 33, 5451-5459.	2.5	134
25	Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 300-304.	7.1	132
26	Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-13.	1.9	103
27	CSE1L/CAS: its role in proliferation and apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2003, 8, 39-44.	4.9	99
28	Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 4240-4245.	7.1	97
29	Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 3075-3079.	7.1	94
30	Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. <i>Protein Engineering, Design and Selection</i> , 1994, 7, 697-704.	2.1	94
31	Expression and Localization of the Multidrug Resistance Protein 5 (MRP5/ABCC5), a Cellular Export Pump for Cyclic Nucleotides, in Human Heart. <i>American Journal of Pathology</i> , 2003, 163, 1567-1577.	3.8	89
32	Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , 2019, 154, 21-31.	3.8	89
33	The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines. <i>Genome Research</i> , 1996, 6, 187-194.	5.5	87
34	Role of Caspases in Immunotoxin-Induced Apoptosis of Cancer Cells. <i>Biochemistry</i> , 1998, 37, 16934-16942.	2.5	86
35	Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. <i>Drug Discovery Today</i> , 2001, 6, 835-839.	6.4	85
36	Role of CAS, a Human Homologue to the Yeast Chromosome Segregation Gene CSE1, in Toxin and Tumor Necrosis Factor Mediated Apoptosis. <i>Biochemistry</i> , 1996, 35, 6891-6899.	2.5	83

#	ARTICLE	IF	CITATIONS
37	Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 51-60.	4.7	75
38	Development of secreted proteins as biotherapeutic agents. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 551-558.	3.1	74
39	Development of Tetraivalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2369-2378.	3.2	73
40	PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10757-10762.	7.1	72
41	Tumor-Antigen-â€œBinding Bispecific Antibodies for Cancer Treatment. <i>Seminars in Oncology</i> , 2014, 41, 653-660.	2.2	70
42	Bispecific digoxigenin-binding antibodies for targeted payload delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 8194-8199.	7.1	68
43	Renaturation of a Single-â€œChain Immunotoxin Facilitated by Chaperones and Protein Disulfide Isomerase. <i>Nature Biotechnology</i> , 1992, 10, 682-685.	17.5	65
44	High expression of a specific T-cell receptor $\hat{A}$ transcript in epithelial cells of the prostate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 9287-9292.	7.1	62
45	A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors. <i>PLoS ONE</i> , 2013, 8, e54923.	2.5	61
46	The human CAS protein which is homologous to the CSE1 yeast chromosome segregation gene product is associated with microtubules and mitotic spindle.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 2670-2674.	7.1	56
47	Bispecific antibodies. <i>Science</i> , 2021, 372, 916-917.	12.6	54
48	Immunotoxins against cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1994, 1198, 27-45.	7.4	53
49	CAS, the Human Homologue of the Yeast Chromosome-Segregation Gene CSE1, in Proliferation, Apoptosis, and Cancer. <i>American Journal of Human Genetics</i> , 1998, 62, 509-513.	6.2	53
50	Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation. <i>Protein Engineering, Design and Selection</i> , 1995, 8, 1323-1331.	2.1	51
51	Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. <i>Cancer Genomics and Proteomics</i> , 2014, 11, 25-38.	2.0	51
52	A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties. <i>Journal of Biological Chemistry</i> , 2014, 289, 18693-18706.	3.4	48
53	Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 1221-1227.	4.1	48
54	Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: Comparison with its single-chain analog. <i>Molecular Immunology</i> , 1995, 32, 249-258.	2.2	47

#	ARTICLE	IF	CITATIONS
55	Characterization of a re-engineered, mesothelin-targeted <i>Pseudomonas</i> exotoxin fusion protein for lung cancer therapy. <i>Molecular Oncology</i> , 2016, 10, 1317-1329.	4.6	45
56	Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-TAC Fv fragment and truncated <i>Pseudomonas</i> exotoxin. <i>International Journal of Cancer</i> , 1994, 58, 142-149.	5.1	44
57	Expression Cloning of cDNAs That Render Cancer Cells Resistant to <i>Pseudomonas</i> and Diphtheria Toxin and Immunotoxins. <i>Molecular Medicine</i> , 1995, 1, 206-216.	4.4	44
58	Recombinant Toxins: New Therapeutic Agents for Cancer. <i>Annals of the New York Academy of Sciences</i> , 1995, 758, 345-354.	3.8	44
59	High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: Correlation with tumor progression. <i>International Journal of Molecular Medicine</i> , 2001, 7, 489-94.	4.0	44
60	Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. <i>Archives of Biochemistry and Biophysics</i> , 2012, 526, 206-218.	3.0	44
61	Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles. <i>Biochemical Journal</i> , 2001, 356, 867-873.	3.7	38
62	Loss of diphthamide pre-activates NF- $\kappa$ B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10732-10737.	7.1	37
63	Expression of the Proliferation and Apoptosis-Associated CAS Protein in Benign and Malignant Cutaneous Melanocytic Lesions. <i>American Journal of Dermatopathology</i> , 1999, 21, 125-128.	0.6	37
64	A bivalent disulfide-stabilized fv with improved antigen binding to erbb2. <i>Journal of Molecular Biology</i> , 1998, 281, 475-483.	4.2	35
65	Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression. <i>Nucleic Acids Research</i> , 2019, 47, 953-969.	14.5	35
66	The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 17-39.	2.0	35
67	The emerging role of new protein scaffold-based agents for treatment of cancer. <i>Cancer Genomics and Proteomics</i> , 2013, 10, 155-68.	2.0	35
68	How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 869-76.	2.3	34
69	Phage display of disulfide-stabilized Fv fragments. <i>Journal of Immunological Methods</i> , 1995, 182, 41-50.	1.4	32
70	Stabilization of a recombinant Fv fragment by base-loop interconnection and VH-VL permutation. <i>Journal of Molecular Biology</i> , 1997, 268, 107-117.	4.2	32
71	Cse1l Is Essential for Early Embryonic Growth and Development. <i>Molecular and Cellular Biology</i> , 2001, 21, 7020-7024.	2.3	32
72	High-throughput Functional Genomics Identifies Genes That Ameliorate Toxicity Due to Oxidative Stress in Neuronal HT-22 Cells. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 834-840.	3.8	31

#	ARTICLE	IF	CITATIONS
73	Effects of TWEAK (TNF Superfamily Member 12) on Differentiation, Metabolism, and Secretary Function of Human Primary Preadipocytes and Adipocytes. <i>Endocrinology</i> , 2009, 150, 5373-5383.	2.8	31
74	A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 547-551.	7.1	30
75	Antisense Inhibition of CAS, the Human Homologue of the Yeast Chromosome Segregation Gene CSE1, Interferes with Mitosis in HeLa Cells. <i>Biochemistry</i> , 1997, 36, 9493-9500.	2.5	29
76	Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. <i>Protein Engineering, Design and Selection</i> , 2012, 25, 571-580.	2.1	28
77	The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 1-19.	2.0	28
78	LIGHT (TNFSF14) inhibits adipose differentiation without affecting adipocyte metabolism. <i>International Journal of Obesity</i> , 2011, 35, 208-216.	3.4	27
79	Influence of GSTT1 and GSTM1 Genotypes on Sunburn Sensitivity. <i>Molecular Diagnosis and Therapy</i> , 2002, 2, 147-154.	3.3	25
80	Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. <i>Nature Communications</i> , 2020, 11, 4974.	12.8	25
81	Effects of Ultrasonic Dispersion Energy on the Preparation of Amorphous SiO2 Nanomaterials for In Vitro Toxicity Testing. <i>Nanomaterials</i> , 2019, 9, 11.	4.1	24
82	Recombinant Immunotoxins: From Basic Research to Cancer Therapy. <i>Methods</i> , 1995, 8, 143-156.	3.8	23
83	MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 1-21.	2.0	23
84	Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles. <i>Biochemical Journal</i> , 2001, 356, 867.	3.7	22
85	Induction of heat shock protein HSPA6 (HSP70) upon HSP90 inhibition in cancer cell lines. <i>FEBS Letters</i> , 2015, 589, 1450-1458.	2.8	22
86	Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes. <i>Cancer Gene Therapy</i> , 2000, 7, 91-96.	4.6	21
87	Recombinant immunotoxins: protein engineering for cancer therapy. <i>Trends in Molecular Medicine</i> , 1996, 2, 439-446.	2.6	20
88	Effects of BCL-2 overexpression on the sensitivity of MCF-7 breast cancer cells to ricin, diphtheria and Pseudomonas toxin and immunotoxins. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 1997, 2, 192-198.	4.9	20
89	Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 3065-3069.	7.1	19
90	Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. <i>MABs</i> , 2016, 8, 562-573.	5.2	19

#	ARTICLE	IF	CITATIONS
91	Recombinant immunotoxins. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 3-9.	2.5	18
92	Apoptosis Induced by <i>Pseudomonas</i> Exotoxin: A Sensitive and Rapid Marker for Gene Delivery in Vivo. <i>Human Gene Therapy</i> , 1999, 10, 923-934.	2.7	18
93	TriFabs™ Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27497-27507.	4.1	18
94	The intriguing options of multispecific antibody formats for treatment of cancer. <i>Cancer Genomics and Proteomics</i> , 2013, 10, 1-18.	2.0	18
95	Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and tcr fv frameworks are very similar in structure. <i>Immunity</i> , 1995, 2, 281-287.	14.3	17
96	The hCSE1/CAS Protein Is Phosphorylated by HeLa Extracts and MEK-1: MEK-1 Phosphorylation May Modulate the Intracellular Localization of CAS. <i>Biochemical and Biophysical Research Communications</i> , 1998, 250, 623-628.	2.1	17
97	Quantification of cell surface proteins with bispecific antibodies. <i>Protein Engineering, Design and Selection</i> , 2013, 26, 645-654.	2.1	17
98	Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress. <i>Redox Biology</i> , 2019, 20, 146-156.	9.0	17
99	Diphthamide-deficiency syndrome: a novel human developmental disorder and ribosomopathy. <i>European Journal of Human Genetics</i> , 2020, 28, 1497-1508.	2.8	17
100	High throughput functional genomics: Identification of novel genes with tumor suppressor phenotypes. <i>International Journal of Cancer</i> , 2005, 113, 434-439.	5.1	16
101	Influence of TBK-1 on tumor angiogenesis and microvascular inflammation. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 7243.	3.0	16
102	Bispecific Antibody Derivatives Based on Full-Length IgG Formats. <i>Methods in Molecular Biology</i> , 2012, 901, 247-263.	0.9	16
103	Importance of diphthamide modified EF2 for translational accuracy and competitive cell growth in yeast. <i>PLoS ONE</i> , 2018, 13, e0205870.	2.5	16
104	Tissue-Specific Alternative Splicing of the CSE1L/CAS (Cellular Apoptosis Susceptibility) Gene. <i>Genomics</i> , 1999, 58, 41-49.	2.9	15
105	Engineered haptens-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery. <i>Immunological Reviews</i> , 2016, 270, 165-177.	6.0	15
106	DPH1 syndrome: two novel variants and structural and functional analyses of seven missense variants identified in syndromic patients. <i>European Journal of Human Genetics</i> , 2020, 28, 64-75.	2.8	15
107	Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. , 1997, 71, 638-644.		14
108	Sequence diversity and functional characterization of the 5' regulatory region of human CYP2C19. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 199-206.	5.7	14

#	ARTICLE	IF	CITATIONS
109	Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 77-83.	1.5	14
110	Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies. <i>FASEB Journal</i> , 2015, 29, 1763-1779.	0.5	14
111	Human-protein-derived peptides for intracellular delivery of biomolecules. <i>Biochemical Journal</i> , 2012, 442, 583-593.	3.7	13
112	Disruption of diphthamide synthesis genes and resulting toxin resistance as a robust technology for quantifying and optimizing CRISPR/Cas9-mediated gene editing. <i>Scientific Reports</i> , 2017, 7, 15480.	3.3	12
113	Fluorescent Citrine-IgG fusion proteins produced in mammalian cells. <i>MAbs</i> , 2010, 2, 648-661.	5.2	11
114	Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization. <i>Bioconjugate Chemistry</i> , 1994, 5, 321-326.	3.6	10
115	Recombinant immunotoxins for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 693-702.	3.1	10
116	PK modulation of haptenylated peptides via non-covalent antibody complexation. <i>Journal of Controlled Release</i> , 2013, 171, 48-56.	9.9	9
117	Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins. <i>Toxins</i> , 2017, 9, 78.	3.4	9
118	Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids. <i>Nucleic Acids Research</i> , 2019, 47, e55-e55.	14.5	9
119	Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing. <i>Biological Chemistry</i> , 2019, 400, 343-350.	2.5	9
120	Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates. <i>Current Cancer Drug Targets</i> , 2016, 16, 639-649.	1.6	9
121	Identification of Twelve Polymorphisms in the Endothelin-1 Gene by Use of Fluorescently Labeled Oligonucleotides and PCR with Restriction Fragment Polymorphism Analysis. <i>Clinical Chemistry</i> , 2004, 50, 448-451.	3.2	8
122	DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity. <i>MAbs</i> , 2019, 11, 1402-1414.	5.2	8
123	Micro RNAs Promoting Growth and Metastasis in Preclinical <i>In Vivo</i> Models of Subcutaneous Melanoma. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 651-667.	2.0	7
124	Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 795-802.	2.5	6
125	Transcytosis of payloads that are non-covalently complexed to bispecific antibodies across the hCMEC/D3 blood-brain barrier model. <i>Biological Chemistry</i> , 2018, 399, 711-721.	2.5	6
126	Down-regulated MicroRNAs in Gastric Carcinoma May Be Targets for Therapeutic Intervention and Replacement Therapy. <i>Anticancer Research</i> , 2021, 41, 4185-4202.	1.1	6



#	ARTICLE	IF	CITATIONS
127	Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies. <i>Biological Chemistry</i> , 2022, 403, 495-508.	2.5	6
128	Translational fidelity and growth of Arabidopsis require stress-sensitive diphthamide biosynthesis. <i>Nature Communications</i> , 2022, 13, .	12.8	6
129	The Contorsbody, an antibody format for agonism: Design, structure, and function. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 1210-1220.	4.1	5
130	A novel DPH5-related diphthamide-deficiency syndrome causing embryonic lethality or profound neurodevelopmental disorder. <i>Genetics in Medicine</i> , 2022, 24, 1567-1582.	2.4	5
131	Hapten-Binding Bispecific Antibodies for the Targeted Delivery of siRNA and siRNA-Containing Nanoparticles. <i>Methods in Molecular Biology</i> , 2016, 1364, 219-234.	0.9	4
132	Common denominator procedure: a novel approach to gene-expression data mining for identification of phenotype-specific genes. <i>Bioinformatics</i> , 2005, 21, 2766-2772.	4.1	3
133	Back-To-Germline (B2G) Procedure for Antibody Devolution. <i>Antibodies</i> , 2019, 8, 45.	2.5	3
134	Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2. <i>Biological Chemistry</i> , 2019, 400, 501-512.	2.5	3
135	<i>Pseudomonas</i> exotoxin antisense RNA selectively kills hepatitis B virus infected cells. <i>World Journal of Gastroenterology</i> , 2008, 14, 2810.	3.3	3
136	Circular RNAs With Efficacy in Preclinical <i>In Vitro</i> and <i>In Vivo</i> Models of Esophageal Squamous Cell Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 283-298.	2.0	3
137	Generation of Fluorescent IgG Fusion Proteins in Mammalian Cells. <i>Methods in Molecular Biology</i> , 2012, 901, 265-276.	0.9	2
138	microRNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in Preclinical <i>In Vivo</i> Models. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 453-468.	2.0	2
139	Gastric Cancer: Identification of microRNAs Inhibiting Druggable Targets and Mediating Efficacy in Preclinical <i>In Vivo</i> Models. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 497-514.	2.0	2
140	Disulfide-Stabilized Fv Fragments. , 2010, , 181-189.		2
141	Medikamente nach Maß: Pharmakogenetik. <i>Biologie in Unserer Zeit</i> , 2002, 32, 344-350.	0.2	1
142	Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 57-73.	0.1	1
143	Abstract LB-212: XGFR, an Fc-engineered dual signaling inhibitor targeting IGF-1R and EGFR. , 2011, , .		1
144	Bispecific Antibodies. , 2017, , 75-97.		1

#	ARTICLE	IF	CITATIONS
145	Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: Presaging Profits. <i>Pharmacogenomics</i> , 2001, 2, 303-305.	1.3	0
146	Functional characterization of the 5' regulatory region of human CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, P60-P60.	4.7	0
147	Stabilization Strategies and Application of Recombinant Fvs and Fv Fusion Proteins. , 2001, , 593-615.		0
148	Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2. <i>Blood</i> , 2010, 116, 4304-4304.	1.4	0